Extended RAS analysis for anti-epidermal growth factor therapy in patients with metastatic colorectal cancer

Cancer Treatment Reviews

Volumn 41, Issue 8, 2015, Pages 653-659

  Hecht, J Randolph ^a   Douillard, Jean Yves ^b   Schwartzberg, Lee ^c   Grothey, Axel ^d   Kopetz, Scott ^e   Rong, Alan ^f   Oliner, Kelly S ^f   Sidhu, Roger ^f  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITÉ DE NANTES   (France)

^c UNIVERSITY OF TENNESSEE HEALTH SCIENCE CENTER   (United States)

^d MAYO CLINIC   (United States)

^e UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^f AMGEN INC   (United States)

Author keywords

Biomarker; Cetuximab; EGFR; Metastatic colorectal cancer; Panitumumab; RAS mutation

Indexed keywords

BEVACIZUMAB; CETUXIMAB; FLUOROURACIL; FOLINIC ACID; IRINOTECAN; K RAS PROTEIN; OXALIPLATIN; PANITUMUMAB; RAS PROTEIN; ANTINEOPLASTIC AGENT; EPIDERMAL GROWTH FACTOR RECEPTOR; GUANOSINE TRIPHOSPHATASE; KRAS PROTEIN, HUMAN; MEMBRANE PROTEIN; MONOCLONAL ANTIBODY; NRAS PROTEIN, HUMAN; ONCOPROTEIN;

EXON; GENE MUTATION; HUMAN; METASTATIC COLORECTAL CANCER; OVERALL SURVIVAL; PREDICTIVE VALUE; PROGNOSIS; PROGRESSION FREE SURVIVAL; REVIEW; THERAPY RESISTANCE; ANTAGONISTS AND INHIBITORS; COLORECTAL NEOPLASMS; GENETICS; METASTASIS; MUTATION; PATHOLOGY; PHARMACOGENETICS; TREATMENT OUTCOME;

ANTIBODIES, MONOCLONAL; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC AGENTS; COLORECTAL NEOPLASMS; GTP PHOSPHOHYDROLASES; HUMANS; MEMBRANE PROTEINS; MUTATION; NEOPLASM METASTASIS; PHARMACOGENETICS; PROGNOSIS; PROTO-ONCOGENE PROTEINS; RAS PROTEINS; RECEPTOR, EPIDERMAL GROWTH FACTOR; TREATMENT OUTCOME;

EID: 84941025652     PISSN: 03057372     EISSN: 15321967     Source Type: Journal    
DOI: 10.1016/j.ctrv.2015.05.008     Document Type: Review

References (70)

1. Grünwald V., Hidalgo M. Developing inhibitors of the epidermal growth factor receptor for cancer treatment. J Natl Cancer Inst 2003, 95(12):851-867.
2. Herbst R.S., Shin D.M. Monoclonal antibodies to target epidermal growth factor receptor-positive tumors: a new paradigm for cancer therapy. Cancer 2002, 94(5):1593-1611.
3. Amado R.G., Wolf M., Peeters M., et al. Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer. J Clin Oncol 2008, 26(10):1626-1634.
4. Jonker D.J., O'Callaghan C.J., Karapetis C.S., et al. Cetuximab for the treatment of colorectal cancer. N Engl J Med 2007, 357(20):2040-2048.
5. Karapetis C.S., Khambata-Ford S., Jonker D.J., et al. K-ras mutations and benefit from cetuximab in advanced colorectal cancer. N Engl J Med 2008, 359(17):1757-1765.
6. Van Cutsem E., Peeters M., Siena S., et al. Open-label phase III trial of panitumumab plus best supportive care compared with best supportive care alone in patients with chemotherapy-refractory metastatic colorectal cancer. J Clin Oncol 2007, 25(13):1658-1664.
7. Keating G.M. Panitumumab: a review of its use in metastatic colorectal cancer. Drugs 2010, 70(8):1059-1078.
8. Blick S.K., Scott L.J. Cetuximab: a review of its use in squamous cell carcinoma of the head and neck and metastatic colorectal cancer. Drugs 2007, 67(17):2585-2607.
9. Price T.J., Peeters M., Kim T.W., et al. Panitumumab versus cetuximab in patients with chemotherapy-refractory wild-type KRAS exon 2 metastatic colorectal cancer (ASPECCT): a randomised, multicentre, open-label, non-inferiority phase 3 study. Lancet Oncol 2014, 15(6):569-579.
10. Wang H.L., Lopategui J., Amin M.B., Patterson S.D. KRAS mutation testing in human cancers: the pathologist's role in the era of personalized medicine. Adv Anat Pathol 2010, 17(1):23-32.
11. Irahara N., Baba Y., Nosho K., et al. NRAS mutations are rare in colorectal cancer. Diagn Mol Pathol 2010, 19(3):157-163.
12. Schubbert S., Shannon K., Bollag G. Hyperactive Ras in developmental disorders and cancer. Nat Rev Cancer 2007, 7(4):295-308.
13. Rojas J.M., Santos E. Ras genes and human cancer: different implications and different roles. Curr Genomics 2002, 3(4):295-311.
14. Der C.J., Finkel T., Cooper G.M. Biological and biochemical properties of human rasH genes mutated at codon 61. Cell 1986, 44(1):167-176.
15. Yarden Y., Sliwkowski M.X. Untangling the ErbB signalling network. Nat Rev Mol Cell Biol 2001, 2(2):127-137.
16. Haigis K.M., Kendall K.R., Wang Y., et al. Differential effects of oncogenic K-Ras and N-Ras on proliferation, differentiation and tumor progression in the colon. Nat Genet 2008, 40(5):600-608.
17. Davies H., Bignell G.R., Cox C., et al. Mutations of the BRAF gene in human cancer. Nature 2002, 417(6892):949-954.
18. Cerami E., Gao J., Dogrusoz U., et al. The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data. Cancer Discov 2012, 2(5):401-404.
19. Di Fiore F., Blanchard F., Charbonnier F., et al. Clinical relevance of KRAS mutation detection in metastatic colorectal cancer treated by cetuximab plus chemotherapy. Br J Cancer 2007, 96(8):1166-1169.
20. Di Fiore F., Van Cutsem E., Laurent-Puig P., et al. Role of KRAS mutation in predicting response, progression-free survival, and overall survival in irinotecan-refractory patients treated with cetuximab plus irinotecan for a metastatic colorectal cancer: analysis of 281 individual data from published series. J Clin Oncol 2008, 26:4035. [abstract].
21. Douillard J.Y., Siena S., Cassidy J., et al. Randomized, phase III trial of panitumumab with infusional fluorouracil, leucovorin, and oxaliplatin (FOLFOX4) versus FOLFOX4 alone as first-line treatment in patients with previously untreated metastatic colorectal cancer: the PRIME study. J Clin Oncol 2010, 28(31):4697-4705.
22. Douillard J.-Y., Siena S., Tabernero J., et al. Overall survival (OS) analysis from PRIME: randomized phase III study of panitumumab (pmab) with FOLFOX4 for first-line metastatic colorectal cancer (mCRC). J Clin Oncol 2013, 31(Suppl.). [abstract 3620].
23. Peeters M., Price T.J., Cervantes A., et al. Randomized phase III study of panitumumab with fluorouracil, leucovorin, and irinotecan (FOLFIRI) compared with FOLFIRI alone as second-line treatment in patients with metastatic colorectal cancer. J Clin Oncol 2010, 28(31):4706-4713.
24. Van Cutsem E., Köhne C.H., Hitre E., et al. Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer. N Engl J Med 2009, 360(14):1408-1417.
25. Bokemeyer C., Bondarenko I., Makhson A., et al. Fluorouracil, leucovorin, and oxaliplatin with and without cetuximab in the first-line treatment of metastatic colorectal cancer. J Clin Oncol 2009, 27(5):663-671.
26. Bokemeyer C., Bondarenko I., Hartmann J.T., et al. Efficacy according to biomarker status of cetuximab plus FOLFOX-4 as first-line treatment for metastatic colorectal cancer: the OPUS study. Ann Oncol 2011, 22(7):1535-1546.
27. Heinemann V., von Weikersthal L.F., Decker T., et al. FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer (FIRE-3): a randomised, open-label, phase 3 trial. Lancet Oncol 2014, 15(10):1065-1075.
28. Hecht J.R., Cohn A., Dakhil S., et al. SPIRITT: a randomized, multicenter, phase II study of panitumumab with FOLFIRI and bevacizumab with FOLFIRI as second-line treatment in patients with unresectable wild type KRAS metastatic colorectal cancer. Clin Colorectal Cancer 2015, 14(2):72-80.
29. NCCN clinical practice guidelines in oncology: colon cancer v.3. National Comprehensive Cancer Network. Available at: ; 2014. [accessed 11.02.14]. http://www.nccn.org/professionals/physician_gls/pdf/colon.pdf.
30. Stallone G., Schena A., Infante B., et al. Sirolimus for Kaposi's sarcoma in renal-transplant recipients. N Engl J Med 2005, 352(13):1317-1323.
31. Vectibix® (panitumumab). Full Prescribing Information, Amgen Inc., Thousand Oaks, CA, 2014.
32. Erbitux® (cetuximab). Full Prescribing Information, ImClone Systems Incorporated and Bristol-Myers Squibb Company, Princeton, NJ, 2013.
33. European Medicines Agency (EMA). Erbitux (cetuximab). In: Summary of product characteristics. Darmstadt, Germany: Merck; 2014.
34. European Medicines Agency (EMA). Vectibix (panitumumab). In: Summary of product characteristics. Thousand Oaks, CA: Amgen; 2013.
35. US Food and Drug Administration. Medical Devices. therascreen KRAS RGQ PCR Kit-P110030. Available at: [accessed 15.07.14]. http://www.fda.gov/MedicalDevices/ProductsandMedicalProcedures/DeviceApprovalsandClearances/Recently-ApprovedDevices/ucm312055.htm.
36. US Food and Drug Administration. Medical Devices. therascreen KRAS RGQ PCR Kit-P110027. Available at: [Accessed 15.07.14]. http://www.fda.gov/MedicalDevices/ProductsandMedicalProcedures/DeviceApprovalsandClearances/Recently-ApprovedDevices/ucm400569.htm.
37. Patel G.S., Karapetis C.S. Personalized treatment for advanced colorectal cancer: KRAS and beyond. Cancer Manage Res 2013, 5:387-400.
38. Loupakis F., Ruzzo A., Cremolini C., et al. KRAS codon 61, 146 and BRAF mutations predict resistance to cetuximab plus irinotecan in KRAS codon 12 and 13 wild-type metastatic colorectal cancer. Br J Cancer 2009, 101(4):715-721.
39. Sorich M.J., Wiese M.D., Rowland A., et al. Extended RAS mutations and anti-EGFR monoclonal antibody survival benefit in metastatic colorectal cancer: a meta-analysis of randomized controlled trials. Ann Oncol 2014, 26(1):13-21.
40. Janakiraman M., Vakiani E., Zeng Z., et al. Genomic and biological characterization of exon 4 KRAS mutations in human cancer. Cancer Res 2010, 70(14):5901-5911.
41. De Roock W., Claes B., Bernasconi D., et al. Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis. Lancet Oncol 2010, 11(8):753-762.
42. Peeters M., Oliner K.S., Parker A., et al. Massively parallel tumor multigene sequencing to evaluate response to panitumumab in a randomized phase III study of metastatic colorectal cancer. Clin Cancer Res 2013, 19(7):1902-1912.
43. Patterson S.D., Peeters M., Siena S., et al. Comprehensive analysis of KRAS and NRAS mutations as predictive biomarkers for single agent panitumumab (pmab) response in a randomized, phase III metastatic colorectal cancer (mCRC) study (20020408). J Clin Oncol 2013, 31(Suppl.). [abstract 3617].
44. Douillard J.Y., Oliner K.S., Siena S., et al. Panitumumab-FOLFOX4 treatment and RAS mutations in colorectal cancer. N Engl J Med 2013, 369(11):1023-1034.
45. Schwartzberg L.S., Rivera F., Karthaus M., et al. PEAK: a randomized, multicenter phase II study of panitumumab plus modified fluorouracil, leucovorin, and oxaliplatin (mFOLFOX6) or bevacizumab plus mFOLFOX6 in patients with previously untreated, unresectable, wild-type KRAS exon 2 metastatic colorectal cancer. J Clin Oncol 2014, 32(21):2240-2247.
46. Ciardiello F., Lenz H.-J., Kohne C.-H., et al. Treatment outcome according to tumor RAS mutation status in CRYSTAL study patients with metastatic colorectal cancer (mCRC) randomized to FOLFIRI with/without cetuximab. J Clin Oncol 2014, 32(5s). [abstract 3506].
47. Bokemeyer C., Kohne C.-H., Ciardiello F., et al. Treatment outcome according to tumor RAS mutation status in OPUS study patients with metastatic colorectal cancer (mCRC) randomized to FOLFOX4 with/without cetuximab. J Clin Oncol 2014, 32(5s). [abstract 3505].
48. Stintzing S, Jung A, Rossius L, et al. Mutations within the EGFR signaling pathway: influence on efficacy in FIRE-3 - a randomized phase III study of FOLFIRI plus cetuximab or bevacizumab as first-line treatment for wild-type (WT) KRAS (exon 2) metastatic colorectal cancer (mCRC) patients. Presented at American Society of Clinical Oncology Gastrointestinal Cancers Symposium; January 16-18, 2014; San Francisco, CA.
49. Lenz H., Niedzwiecki D., Innocenti F., et al. CALGB/SWOG 80405: phase III trial of irinotecan/5-FU/leucovorin (FOLFIRI) or of oxaliplatin/5-FU/leucovorin (mFOLFOX6) with bevacizumab (BV) or cetuximab (CET) for patients (pts) with untreated metastatic adenocarcinoma of the colon or rectum (mCRC): expanded RAS analyses. Ann Oncol 2014, 25(Suppl. 5). [abstract 501O].
50. Peeters M, Oliner KS, Price TJ, et al. Updated analysis of KRAS/NRAS and BRAF mutations in study 20050181 of panitumumab (pmab)+FOLFIRI for second-line treatment (tx) of metastatic colorectal cancer (mCRC). Presented at American Society of Clinical Oncology Annual Meeting; May 30-June 3, 2014. Chicago, IL.
51. Misale S., Yaeger R., Hobor S., et al. Emergence of KRAS mutations and acquired resistance to anti-EGFR therapy in colorectal cancer. Nature 2012, 486(7404):532-536.
52. Diaz L.A., Williams R.T., Wu J., et al. The molecular evolution of acquired resistance to targeted EGFR blockade in colorectal cancers. Nature 2012, 486(7404):537-540.
53. Bettegowda C., Sausen M., Leary R.J., et al. Detection of circulating tumor DNA in early- and late-stage human malignancies. Sci Transl Med 2014, 6(224):224ra24.
54. Misale S., Arena S., Lamba S., et al. Blockade of EGFR and MEK intercepts heterogeneous mechanisms of acquired resistance to anti-EGFR therapies in colorectal cancer. Sci Transl Med 2014, 6(224):224ra26.
55. Yuan Z.X., Wang X.Y., Qin Q.Y., et al. The prognostic role of BRAF mutation in metastatic colorectal cancer receiving anti-EGFR monoclonal antibodies: a meta-analysis. PLoS ONE 2013, 8(6):e65995.
56. Bokemeyer C., Van Cutsem E., Rougier P., et al. Addition of cetuximab to chemotherapy as first-line treatment for KRAS wild-type metastatic colorectal cancer: pooled analysis of the CRYSTAL and OPUS randomised clinical trials. Eur J Cancer 2012, 48(10):1466-1475.
57. Tran B., Kopetz S., Tie J., et al. Impact of BRAF mutation and microsatellite instability on the pattern of metastatic spread and prognosis in metastatic colorectal cancer. Cancer 2011, 117(20):4623-4632.
58. Di Nicolantonio F., Martini M., Molinari F., et al. Wild-type BRAF is required for response to panitumumab or cetuximab in metastatic colorectal cancer. J Clin Oncol 2008, 26(35):5705-5712.
59. Van Cutsem E., Kohne C.H., Lang I., et al. Cetuximab plus irinotecan, fluorouracil, and leucovorin as first-line treatment for metastatic colorectal cancer: updated analysis of overall survival according to tumor KRAS and BRAF mutation status. J Clin Oncol 2011, 29(15):2011-2019.
60. Pentheroudakis G., Kotoula V., De Roock W., et al. Biomarkers of benefit from cetuximab-based therapy in metastatic colorectal cancer: interaction of EGFR ligand expression with RAS/RAF, PIK3CA genotypes. BMC Cancer 2013, 13:49.
61. Khambata-Ford S., Garrett C.R., Meropol N.J., et al. Expression of epiregulin and amphiregulin and K-ras mutation status predict disease control in metastatic colorectal cancer patients treated with cetuximab. J Clin Oncol 2007, 25(22):3230-3237.
62. De Roock W., De Vriendt V., Normanno N., Ciardiello F., Tejpar S. KRAS, BRAF, PIK3CA, and PTEN mutations: implications for targeted therapies in metastatic colorectal cancer. Lancet Oncol 2011, 12(6):594-603.
63. Perrone F., Lampis A., Orsenigo M., et al. PI3KCA/PTEN deregulation contributes to impaired responses to cetuximab in metastatic colorectal cancer patients. Ann Oncol 2009, 20(1):84-90.
64. Sartore-Bianchi A., Martini M., Molinari F., et al. PIK3CA mutations in colorectal cancer are associated with clinical resistance to EGFR-targeted monoclonal antibodies. Cancer Res 2009, 69(5):1851-1857.
65. Wong N.A., Gonzalez D., Salto-Tellez M., et al. RAS testing of colorectal carcinoma - a guidance document from the Association of Clinical Pathologists Molecular Pathology and Diagnostics Group. J Clin Pathol 2014, 67(9):751-757.
66. Van Cutsem E., Cervantes A., Nordlinger B., Arnold D. Metastatic colorectal cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2014, 25(Suppl. 3):iii1-iii9.
67. European Medicines Agency. Vectibix European Public Assessment Report. Summary of Product Characteristics; 2014.
68. European Medicines Agency. Erbitux European Public Assessment Report. Summary of Product Characteristics; 2014.
69. Cancer Genome Atlas N Comprehensive molecular characterization of human colon and rectal cancer. Nature 2012, 487(7407):330-337.
70. Tougeron D., Lecomte T., Pages J.C., et al. Effect of low-frequency KRAS mutations on the response to anti-EGFR therapy in metastatic colorectal cancer. Ann Oncol 2013, 24(5):1267-1273.